VALUE-BASED CANCER CARE Trademark

Trademark Overview

On Monday, January 11, 2010, a trademark application was filed for VALUE-BASED CANCER CARE with the United States Patent and Trademark Office. The USPTO has given the VALUE-BASED CANCER CARE trademark a serial number of 77909171. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, October 13, 2017. This trademark is owned by Engage Healthcare Communications, LLC. The VALUE-BASED CANCER CARE trademark is filed in the Advertising, Business and Retail Services category with the following description:

advertising services, namely, providing advertising space in magazines, newsletters, feature reports, supplements and web sites that concern information in the fields of oncology and cancer
value-based cancer care

General Information

Serial Number77909171
Word MarkVALUE-BASED CANCER CARE
Filing DateMonday, January 11, 2010
Status710 - CANCELLED - SECTION 8
Status DateFriday, October 13, 2017
Registration Number3927515
Registration DateTuesday, March 8, 2011
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 21, 2010

Trademark Statements

Goods and Servicesadvertising services, namely, providing advertising space in magazines, newsletters, feature reports, supplements and web sites that concern information in the fields of oncology and cancer

Classification Information

International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, October 13, 2017
Primary Code035
First Use Anywhere DateSaturday, January 2, 2010
First Use In Commerce DateSaturday, May 1, 2010

Trademark Owner History

Party NameEngage Healthcare Communications, LLC
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressMonroe Twp., NJ 08831
Party NameEngage Healthcare Communications, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMonroe Twp., NJ 08831
Party NameEngage Healthcare Communications, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressMonroe Twp., NJ 08831

Trademark Events

Event DateEvent Description
Wednesday, February 19, 2020CANCELLATION TERMINATED NO. 999999
Wednesday, February 19, 2020CANCELLATION DENIED NO. 999999
Friday, October 13, 2017CANCELLED SEC. 8 (6-YR)
Tuesday, July 18, 2017ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, July 18, 2017TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, March 8, 2016COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Thursday, April 19, 2012TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, December 20, 2011CANCELLATION INSTITUTED NO. 999999
Tuesday, March 8, 2011REGISTERED-PRINCIPAL REGISTER
Tuesday, December 21, 2010OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 21, 2010PUBLISHED FOR OPPOSITION
Saturday, November 13, 2010LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, November 10, 2010APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, October 12, 2010TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, October 11, 2010CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, October 11, 2010TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, October 5, 2010NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Monday, October 4, 2010USE AMENDMENT ACCEPTED
Friday, October 1, 2010AMENDMENT TO USE PROCESSING COMPLETE
Friday, October 1, 2010USE AMENDMENT FILED
Friday, October 1, 2010ASSIGNED TO LIE
Thursday, September 30, 2010TEAS AMENDMENT OF USE RECEIVED
Monday, April 12, 2010NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, April 12, 2010NON-FINAL ACTION E-MAILED
Monday, April 12, 2010NON-FINAL ACTION WRITTEN
Monday, April 5, 2010ASSIGNED TO EXAMINER
Friday, January 15, 2010NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, January 14, 2010NEW APPLICATION ENTERED IN TRAM

Related Keywords

care cancer based value advertising concern sites information fields oncology supplements feature namely